• Trendlyne logo
  • Markets
  • Alerts
  • F&O
  • MF
  • Reports
  • Screeners
  • Subscribe
  • Superstars
  • Portfolio
  • Watchlist
  • Insider Trades
  • Results
  • Data Downloader
  • Events Calendar
  • What's New
  • Explore
  • FAQs
  • Widgets
More
    Search stocks
    IND USA
    IND
    IND
    IND
    USA
    • Stocks
    • Futures & Options
    • Mutual Funds
    • News
    • Fundamentals
    • Reports
    • Corporate Actions
    • Alerts
    • Shareholding
    logo
    Cipla Ltd.
    29 Jan 2025
    1575.80
    -0.15%
    Cipla Q3 Results 2025 on 29 Jan, 2025: profit rise by 48.74% YOY, profit at 1570.51 crore and revenue at 7072.97 crore
    Cipla Q3 Results 2025 on 29 Jan, 2025: profit rise by 48.74% YOY, profit at 1570.51 crore and revenue at 7072.97 crore
    livemint
    Cipla Q3 Results 2025 on 29 Jan, 2025: Revenue increased by 7.1% YoY & profit increased by 48.74% YoY, profit at 1570.51 crore and revenue at 7072.97 crore
    Copy LinkShare onShare on Share on Share on
    Deven Choksey released a Hold report for Cipla Ltd. with a price target of 1570.0 on 08 Sep, 2025.
    Brokerages divided on Cipla despite strong Q3 earnings beat; buy or sell?
    Business Standard | 29 Jan 2025 6 more
    Cipla expects to end FY25 exceeding margin guidance, beats Q3 earnings estimates
    livemint | 28 Jan 2025
    India's Cipla beats Q3 profit view as strong domestic demand offset weak US sales
    livemint | 28 Jan 2025
    Cipla Q3 result: PAT soars 48.7% to Rs 1,570.5 cr , revenue grows 7.1%
    Business Standard | 28 Jan 2025
    Cipla Q3 result: Profit up 49% at Rs 1,571 cr on strong demand in N America
    Business Standard | 28 Jan 2025
    Cipla Q3 Results: Profit Rises 49%, Beats Estimates
    NDTV Profit | 28 Jan 2025
    Cipla Q3 Results: Net profit jumps 48% YoY to 1,571 crore; revenue improves 8%
    livemint | 28 Jan 2025
    logo
    Ipca Laboratories Ltd.
    28 Jan 2025
    High Gain High Volume
    1441.00
    7.47%
    Buy or sell stocks: Mehta Equities recommends short selling these 3 stocks in a volatile market
    Buy or sell stocks: Mehta Equities recommends short selling these 3 stocks in a volatile market
    livemint
    Buy or sell stocks: Riyank Arora of Mehta Equities recommends short selling Ipca Laboratories Ltd, Sun Pharmaceutical Industries Ltd, and H.G. Infra Engineering Ltd.
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors decreased from 294 to 270 in Jun 2025 qtr
    logo
    Granules India Ltd.
    28 Jan 2025
    543.40
    0.05%
    Granules India To Offset Gagillapur Facility Delays With New Europe, US Launches
    Granules India To Offset Gagillapur Facility Delays With New Europe, US Launches
    NDTV Profit
    Approvals for four new launches from Granules's US facility have been secured and the fifth approval is awaited.
    Copy LinkShare onShare on Share on Share on
    Granules India Ltd. is trading above all available SMAs
    logo
    Pfizer Ltd.
    27 Jan 2025
    5107.50
    -1.64%
    Pfizer Dodges Challenge to Its Board in Battle With Starboard
    Pfizer Dodges Challenge to Its Board in Battle With Starboard
    livemint
    Pfizer Inc. got a reprieve at least for now in its battle with activist investor Starboard Value LP, according to people familiar with the matter.
    Copy LinkShare onShare on Share on Share on
    Pfizer Ltd. is trading above its 200 day SMA of 4895.2
    logo
    Torrent Pharmaceuticals Ltd.
    27 Jan 2025
    3629.20
    1.73%
    Torrent Pharma Q3 Results : PL Capital Recommends 'Accumulate' On The Stock, Hikes Target Price Here's Why
    Torrent Pharma Q3 Results : PL Capital Recommends 'Accumulate' On The Stock, Hikes Target Price Here's Why
    NDTV Profit
    Torrent Pharma continues to explore inorganic opportunities which will be key for stock performance, says the brokerage.
    Copy LinkShare onShare on Share on Share on
    Torrent Pharmaceutic.. has an average target of 3746.00 from 5 brokers.
    logo
    Laurus Labs Ltd.
    27 Jan 2025
    10-year high
    932.10
    0.96%
    Laurus Labs shares down 15% on profit booking post Q3 earnings; Should you buy or sell?
    Laurus Labs shares down 15% on profit booking post Q3 earnings; Should you buy or sell?
    livemint
    Goldman Sachs has retained its Sell' rating on Laurus Labs, setting a price target of 475. The brokerage noted that although the management did not offer specific revenue guidance for FY2025.
    Copy LinkShare onShare on Share on Share on
    Laurus Labs Ltd. has gained 43.18% in the last 3 Months
    Laurus Labs Shares Hit Two-Month Low Amid US Foreign Aid Pause, ARV Sales Concerns
    NDTV Profit | 27 Jan 2025 1 more
    Laurus Labs plunges 15% as analysts warn of overvaluation; buy, sell, hold?
    Business Standard | 27 Jan 2025
    logo
    Supriya Lifescience Ltd.
    27 Jan 2025
    High Gain High Volume
    726.20
    5.42%
    Supriya Lifescience plummets 6% after Q3FY25 results; details here
    Business Standard
    Supriya Lifescience share slipped 5.65 per cent at Rs 661.20 a piece on the BSE in Monday's intraday trade despite the pharma company reporting strong quarterly earnings for the financial year 2024-25
    Copy LinkShare onShare on Share on Share on
    Supriya Lifescience Ltd. is trading above all available SMAs
    logo
    Cohance Lifesciences Ltd.
    27 Jan 2025
    Block Deal Insider Trades
    909.40
    -0.36%
    Suven Pharma looks for 6x increase in revenue by FY35
    Suven Pharma looks for 6x increase in revenue by FY35
    Business Today
    Looking to the future, Suven's Horizon 2 initiative which includes plans to incorporate capabilities in flow chemistry, messenger ribonucleic acid (mRNA), and peptides by fiscal year 2030 is expected to enhance the company's position in advanced drug modalities.
    Copy LinkShare onShare on Share on Share on
    Cohance Lifesciences.. has an average target of 1346.50 from 2 brokers.
    logo
    Mankind Pharma Ltd.
    27 Jan 2025
    2660.60
    0.85%
    Mankind Pharma Q3 Results Review: Systematix Maintains 'Hold' On The Stock, Revises Target Price Here's Why
    Mankind Pharma Q3 Results Review: Systematix Maintains 'Hold' On The Stock, Revises Target Price Here's Why
    NDTV Profit
    Mankind is addressing growth challenges in IPM through inorganic additions, but the brokerage expects the same to be margin dilutive in the near to medium term.
    Copy LinkShare onShare on Share on Share on
    Mankind Pharma Ltd. has an average target of 2840.50 from 2 brokers.
    logo
    Cipla Ltd.
    27 Jan 2025
    1575.80
    -0.15%
    Cipla Q3 Preview: Supply disruptions, market share loss to weigh on topline
    Business Standard
    Cipla Q3 Preview: India's third largest pharmaceutical company, Cipla, is scheduled to deliver its October-December quarterly earnings for the financial year 2024-25 (Q3FY25) on Tuesday, January 28
    Copy LinkShare onShare on Share on Share on
    Number of FII/FPI investors increased from 1114 to 1124 in Jun 2025 qtr.
    more
    loading
    Trendlyne Logo Trendlyne
    Stay ahead of the market
    Markets Today
    • Nifty 50 today
    • Sensex today
    • Latest Quarterly results
    • FII & DII data today
    Dashboard
    • Industry & Sector analysis
    • ETFs
    • Mutual Funds
    • Bullish & Bearish spread
    • Global Indices
    Tools
    • Compare stocks
    • Widgets
    • Data Downloader
    • Excel Connect
    IPOs
    • Dashboard (Mainboard & SME)
    • Upcoming IPOs
    • Recently Listed IPOs
    • Most Successful IPOs
    Upcoming IPOs
    • JD Cables
    • GK Energy
    • Siddhi Cotspin
    Quick Links
    • Contact us
    • Blogs
    • FAQs
    Company
    • Privacy
    • Terms of Use
    • Disclaimer
    Trendlyne Products
    • Starfolio
    • SmartOptions
    • Trendlyne US Global
    Get Mobile App
    • Android
    • iOS

    Copyright © 2025 Giskard Datatech Pvt Ltd